Literature DB >> 20346983

Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3.

Jason Brayer1, Fengdong Cheng, Hongwei Wang, Pedro Horna, Ildefonso Vicente-Suarez, Javier Pinilla-Ibarz, Eduardo M Sotomayor.   

Abstract

CD8 T cell tolerance, once thought to be largely a result of clonal deletion, is now appreciated to be much more complex, additionally involving multiple permutations of partial loss of effector function in residual clonal populations. This is especially important in the context of tumor immunity, in which persistent tolerized cytotoxic CD8 T cells (CTL), if reactivated, could potentially mount a protective response. Previously we have shown that antigen-presenting cells (APCs) with a targeted disruption of STAT3 break tolerance in CD4 T cells. Here we evaluate the STAT3-defective APC in terms of its ability to induce a productive CTL response. Our data demonstrate that macrophages derived from conditional STAT3 knockout mice are superior to wild-type macrophages in terms of their ability to prime cognate CTL responses, and to cross-present tumor-derived antigen to CTLs in vitro. CTLs cultured with STAT3-deficient APCs demonstrated a stronger proliferative response and produced increased amounts of IFN-gamma and TNF-alpha, all of which have been shown to be diminished in tumor-tolerized CD8 T cells. Targeting STAT3 signaling represents therefore an enticing strategy to augment CTL responses in the tumor-bearing host.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346983      PMCID: PMC2906450          DOI: 10.1016/j.imlet.2010.03.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  24 in total

1.  Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction.

Authors:  V Vezys; S Olson; L Lefrançois
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

2.  A critical role for Stat3 signaling in immune tolerance.

Authors:  Fengdong Cheng; Hong-Wei Wang; Alex Cuenca; Mei Huang; Tomar Ghansah; Jason Brayer; William G Kerr; Kiyoshi Takeda; Shizuo Akira; Stephen P Schoenberger; Hua Yu; Richard Jove; Eduardo M Sotomayor
Journal:  Immunity       Date:  2003-09       Impact factor: 31.745

3.  IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes.

Authors:  D S Finbloom; K D Winestock
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

4.  Peptide-induced deletion of CD8 T cells in vivo occurs via apoptosis in situ.

Authors:  C Koniaras; S R Bennett; F R Carbone; W R Heath; A M Lew
Journal:  Int Immunol       Date:  1997-10       Impact factor: 4.823

5.  Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

Authors:  R E Toes; R Offringa; R J Blom; C J Melief; W M Kast
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

6.  Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

Authors:  Alfred Zippelius; Pascal Batard; Verena Rubio-Godoy; Gilles Bioley; Danielle Liénard; Ferdy Lejeune; Donata Rimoldi; Philippe Guillaume; Norbert Meidenbauer; Andreas Mackensen; Nathalie Rufer; Norbert Lubenow; Daniel Speiser; Jean-Charles Cerottini; Pedro Romero; Mikaël J Pittet
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

7.  Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

Authors:  Lyse A Norian; Paulo C Rodriguez; Leigh A O'Mara; Jovanny Zabaleta; Augusto C Ochoa; Marina Cella; Paul M Allen
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

8.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

9.  Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells.

Authors:  C Kurts; H Kosaka; F R Carbone; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

10.  CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function.

Authors:  Claes Ohlén; Michael Kalos; Laurence E Cheng; Aaron C Shur; Doley J Hong; Bryan D Carson; Niels C T Kokot; Cara G Lerner; Blythe D Sather; Eric S Huseby; Philip D Greenberg
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

View more
  14 in total

1.  Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.

Authors:  Fengdong Cheng; Hongwei Wang; Pedro Horna; Zi Wang; Bijal Shah; Eva Sahakian; Karrune V Woan; Alejandro Villagra; Javier Pinilla-Ibarz; Said Sebti; Mitchell Smith; Jianguo Tao; Eduardo M Sotomayor
Journal:  Cancer Res       Date:  2012-06-22       Impact factor: 12.701

2.  Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model.

Authors:  Yang Cao; Xiaoxi Zhou; Mi Zhou; Danmei Xu; Quanfu Ma; Peilin Zhang; Xiaoyuan Huang; Qinlu Li; Ding Ma; Jianfeng Zhou
Journal:  Cancer Biol Ther       Date:  2014-06-10       Impact factor: 4.742

3.  CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation.

Authors:  Wang Zhang; Chunyan Zhang; Wenzhao Li; Jiehui Deng; Andreas Herrmann; Saul J Priceman; Wei Liang; Shudan Shen; Sumanta K Pal; Dave S B Hoon; Hua Yu
Journal:  Eur J Immunol       Date:  2014-11-10       Impact factor: 5.532

4.  Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.

Authors:  Caglar Cekic; Yuan-Ji Day; Duygu Sag; Joel Linden
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

5.  Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth.

Authors:  Devikala Gurusamy; Jerilyn K Gray; Peterson Pathrose; Rishikesh M Kulkarni; Fred D Finkleman; Susan E Waltz
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

6.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Authors:  Andreas Herrmann; Saul J Priceman; Piotr Swiderski; Maciej Kujawski; Hong Xin; Gregory A Cherryholmes; Wang Zhang; Chunyan Zhang; Christoph Lahtz; Claudia Kowolik; Steve J Forman; Marcin Kortylewski; Hua Yu
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 7.  STAT3 activation: A key factor in tumor immunoescape.

Authors:  Cédric Rébé; Frédérique Végran; Hélène Berger; François Ghiringhelli
Journal:  JAKSTAT       Date:  2013-01-01

8.  Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.

Authors:  María Marcela Barrio; Riad Abes; Marina Colombo; Gabriela Pizzurro; Charlotte Boix; María Paula Roberti; Emmanuelle Gélizé; Mariana Rodriguez-Zubieta; José Mordoh; Jean-Luc Teillaud
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

9.  M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer.

Authors:  Xiaoyi Huang; Fang Yuan; Meihua Liang; Hui-Wen Lo; Mari L Shinohara; Cary Robertson; Pei Zhong
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

Review 10.  Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.

Authors:  Powell Perng; Michael Lim
Journal:  Front Oncol       Date:  2015-07-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.